The 4 most recent market catalysts affecting $TCRX, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 8, 2026
Corporate Catalyst
Bearish
Impact 75
HC Wainwright & Co. Downgrades TScan Therapeutics to Neutral, Lowers Price Target to $1
HC Wainwright & Co. analyst Andres Y. Maldonado downgraded TScan Therapeutics (TCRX) from a 'Buy' rating to 'Neutral' and drastically cut the price target from $7 to $1. This actio…
Sep 3, 2026
Corporate Catalyst
Bearish
Impact 75
Wedbush Downgrades TScan Therapeutics to Neutral, Lowers Price Target to $1
Wedbush analyst David Nierengarten downgraded TScan Therapeutics (TCRX) from Outperform to Neutral and slashed the price target from $5 to $1. This significant downgrade and drasti…
Sep 2, 2026
Macro/Central Bank
Bullish
Impact 65
Crude Oil Moves Higher; US Factory Orders Rise In July
The filing indicates a generally positive economic backdrop with US factory orders exceeding expectations and a substantial draw in crude oil inventories, suggesting robust industr…
Aug 12, 2026
Corporate Catalyst
Bearish
Impact 92
TScan Therapeutics Q2 EPS $(0.23) Misses $(0.21) Estimate, Sales $1.051M Miss $1.667M Estimate
TScan Therapeutics (TCRX) announced Q2 earnings that significantly underperformed analyst expectations. The company reported a larger loss per share than anticipated and sales that…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.